RxDoctor Payments Data

Prasanna Sugathan, MD

Cardiovascular Disease · Lake Charles, LANPI 1598847733

Payments from drug & device makers

$2,121in general payments, 2019–2025

Across 59 payments — averaging $35.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$513
  • Heartflow, Inc.$239
  • Esperion Therapeutics, Inc.$235
  • AstraZeneca$223
  • Boehringer Ingelheim$189
  • Boston Scientific$180
  • plus $541 from 10 others

What the payments were for

  • Food & beverage$2,121100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,121 in reported general payments places this provider in the 40th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$435,168
Medicare patients
1,594
Services billed
5,537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban70$72,063
EntrestoSacubitril/Valsartan71$63,844
JardianceEmpagliflozin12$12,256
NexletolBempedoic Acid22$11,941
XareltoRivaroxaban14$10,328
Ezetimibe265$5,054
Rosuvastatin Calcium260$3,041
Metoprolol Succinate198$2,349
Losartan Potassium149$1,542
Spironolactone119$910
Carvedilol175$813
Flecainide Acetate18$638
Metoprolol Tartrate52$427
Nitroglycerin27$422
Amlodipine Besylate94$417

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$513$63,84471 claims
Boehringer IngelheimJardiance$189$12,25612 claims
Esperion Therapeutics, Inc.Nexletol$235$11,94122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in Lake Charles

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →